Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Breast cancer, early stage

1375 - Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments – a population-based study


28 Sep 2019


Poster Discussion - Breast cancer, early stage


Nienke De Glas


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


N. De Glas1, E. Bastiaannet2, A. de Boer3, S. Siesling4, G. Liefers2, J. Portielje1

Author affiliations

  • 1 Medical Oncology, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 2 Surgery, Leiden University Medical Center, 2300RC - Leiden/NL
  • 3 Surgery, Leids Universitair Medisch Centrum (LUMC), 2300RC - Leiden/NL
  • 4 Research, Netherlands Comprehensive Cancer Organization, 3511DT - Utrecht/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1375


The number of older patients with breast cancer is rapidly increasing. A previous study showed that in the Netherlands, between 1990 and 2005, survival of older patients with breast cancer did not improve in contrast to younger patients. In recent years, scientific evidence in the older age group has increased and specific guidelines for older women with breast cancer have been developed. The aim of this study was to assess recent survival outcomes of older patients with breast cancer compared to younger patients.


All patients with stage I-IV breast cancer between 2000 and 2017 were included from the Netherlands cancer registry. We assessed changes in treatments over time using logistic regression models. We calculated the changes in relative survival as proxy for breast cancer mortality, stratified by age and stage.


We included 239,992 patients. Relative survival improved over time for patients in the youngest age-group for all stages. In patients aged 65-75 years, relative survival adjusted for tumour characteristics did not improve in stage I-II but did improve in stage III (RER 0.98, 95% C.I. 0.96-1.00, p = 0.046). Concurrently, was prescribed in an increasing proportion of patients aged 65-75 years (33.6% in 2000 to 52.7, p < 0.001). In patients aged 75 years or older, relative survival did not improve in patients with stage I/II or stage III disease, nor did treatment strategies change.


This study shows that over time, the relative survival of patients aged 65-75 years with advanced breast cancer has improved, and concurrently, prescription of systemic treatment increased. These data suggest that older patients with advanced breast cancer do benefit from adjuvant systemic treatment. In order to further improve survival of patients >75 as well, future studies should focus on individualizing treatments based on concomitant comorbidity, geriatric parameters and the risk toxicity of treatments.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Leiden University Medical Center, Department of Medical Oncology, Geriatric Oncology Research Group.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.